Rapport Therapeutics Operating Income Over Time
| RAPP Stock | 26.93 0.99 3.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rapport Therapeutics Performance and Rapport Therapeutics Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rapport Therapeutics. If investors know Rapport will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rapport Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rapport Therapeutics is measured differently than its book value, which is the value of Rapport that is recorded on the company's balance sheet. Investors also form their own opinion of Rapport Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rapport Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rapport Therapeutics' market value can be influenced by many factors that don't directly affect Rapport Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rapport Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rapport Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rapport Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Rapport Therapeutics and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Phathom Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (22.2 M) | (65 M) | (117.9 M) | (183.9 M) | (155.1 M) | (213 M) | (213 M) | (191.7 M) | (182.1 M) |
| KOD | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (25.5 M) | (26.4 M) | (49.2 M) | (136 M) | (267.1 M) | (341.4 M) | (277.3 M) | (186.8 M) | (168.2 M) | (176.6 M) |
| PHAT | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (106.2 M) | (125.7 M) | (135.1 M) | (172.4 M) | (167.3 M) | (277.5 M) | (249.7 M) | (237.2 M) |
| XNCR | (9.5 M) | (9.5 M) | (6.2 M) | (10.5 M) | (16.5 M) | (18.3 M) | 22.5 M | (53.6 M) | (79.4 M) | 13.8 M | (76.8 M) | 43.8 M | (82.5 M) | (138.6 M) | (178.4 M) | (160.6 M) | (152.5 M) |
| BBOT | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (3.5 K) | (64.8 M) | (80.9 M) | (72.8 M) | (69.1 M) |
| ANAB | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | 4.9 M | (3.3 M) | (3 M) | (28.8 M) | (66.7 M) | (107.4 M) | (23.9 M) | (56.8 M) | (115.2 M) | (164.4 M) | (114.9 M) | (103.5 M) | (98.3 M) |
| URGN | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (4.4 M) | (12.4 M) | 798 K | (19.9 M) | (77.2 M) | (109.5 M) | (126.7 M) | (92.3 M) | (79 M) | (65.5 M) | (96.8 M) | (87.1 M) | (91.5 M) |
| OCS | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (13.2 M) | (32.4 M) | (80.7 M) | (73.2 M) | (65.9 M) | (69.2 M) |
| SEPN | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | 2.1 M | (80.8 M) | (72.7 M) | (69.1 M) |
Rapport Therapeutics and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Phathom Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Rapport Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rapport Therapeutics Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Rapport Therapeutics Common | RAPP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1325 Boylston Street, |
| Exchange | NASDAQ Exchange |
null 26.93
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.